Matinas Biopharma Holdings, INC

Matinas BioPharma Holdings, Inc. announced the immediate termination of its At-The-Market Sales Agreement with BTIG, LLC, effective July 23, 2026, with no associated termination penalties.

Matinas BioPharma Holdings, Inc. announces a strategic business combination with GH Power Inc. to form a clean energy company, alongside the sale of its LNC platform and MAT2203 to Azurity Pharmaceuticals.

Matinas BioPharma has been granted a compliance plan period until October 2027 by the NYSE American following notice of non-compliance with stockholders' equity standards.

Matinas BioPharma Holdings, Inc. received a notice from NYSE American for failing to meet continued listing standards, with a deadline to submit a compliance plan.

Matinas BioPharma Holdings, Inc. announced that its CEO, Jerome D. Jabbour, will assume the interim Chief Financial Officer role following the resignation of Keith Kucinski.

Matinas BioPharma Holdings, Inc. has amended its CEO's employment agreement, extending retention bonus triggers and modifying change-in-control definitions.

Matinas BioPharma reports Q1 2026 net loss of $1.9 million and warns of substantial doubt regarding its ability to continue as a going concern.

Matinas BioPharma Holdings, Inc. reported a net loss of $1.532 million for Q3 2025 and $8.433 million for the nine months ended September 30, 2025, with substantial doubt about its ability to continue as a going concern.

Matinas BioPharma Holdings, Inc. reported reduced net losses and operating expenses for Q2 2025, but disclosed substantial doubt about its ability to continue as a going concern.

Matinas BioPharma reports a net loss for Q1 2025 and is actively seeking strategic partnerships to monetize its assets and manage its cash resources.

Matinas BioPharma has ceased all product development and reduced its workforce by 80% following the termination of negotiations for its lead drug candidate, MAT2203.

Matinas BioPharma reported a net loss of $11.5 million for the first half of 2024 and faces substantial doubt about its ability to continue as a going concern.

Matinas BioPharma's 10-K filing details its capital structure, strategic shift towards partnering for MAT2203, and ongoing efforts to explore strategic alternatives.

Matinas BioPharma's 10-K filing outlines the company's capital structure, including authorized common and preferred stock, and details anti-takeover provisions.

GH Power and TKMS are evaluating clean energy technology integration for Canada's Future Patrol Submarine Project, potentially securing non-dilutive funding for GH Power.

Matinas BioPharma Holdings, Inc. announced a business combination with GH Power Inc., a clean energy and critical minerals company, aiming to list on the NYSE American.

Matinas BioPharma Holdings, Inc. has filed an SEC Form 425, providing disclosures related to its business and operations.

GH Power and Matinas BioPharma Holdings, Inc. have entered into a definitive business combination agreement to form a new Ontario-based public company, GH Power International.

Matinas BioPharma Holdings, Inc. announced a business combination with GH Power Inc. to form a clean energy company, alongside the sale of its LNC platform and MAT2203 to Azurity Pharmaceuticals.

Director Edward Neugeboren acquired stock options in Matinas BioPharma Holdings, Inc. subject to stockholder approval of the 2025 Equity Incentive Plan.

Matinas BioPharma Holdings seeks stockholder approval for a reverse stock split, an increase in authorized shares, and a new equity incentive plan at its upcoming annual meeting.

Matinas BioPharma is holding a special meeting on April 4, 2025, to seek stockholder approval for a stock issuance that could result in a change of control, as well as to ratify the appointment of its independent auditor.

Hezbay Holdings LLC and Ari Kluger have withdrawn from a joint filing agreement regarding their stake in Matinas BioPharma Holdings, Inc. due to personal reasons.

A group of investors, including Sanitam Partners LLC, Platinum Point Capital, LLC, and HEZBAY Holdings LLC, have completed a second closing of a purchase agreement with Matinas BioPharma Holdings, Inc., acquiring additional preferred stock and warrants, while adhering to a 9.99% beneficial ownership cap.

Matinas BioPharma Holdings, Inc. has filed an amendment to its Schedule 13D, detailing the second closing of a private placement that significantly increases the potential beneficial ownership of Pembroke & Partners LLC and Robert J. Eide, subject to a 9.99% beneficial ownership cap.

Pembroke & Partners LLC and Robert J. Eide have disclosed a significant beneficial ownership stake in Matinas BioPharma Holdings, Inc., acquiring preferred stock and warrants in a private placement, with intentions to actively engage with management and potentially seek board representation.

A group of investors, including Sanitam Partners LLC, HEZBAY Holdings LLC, and Platinum Point Capital, LLC, has disclosed a significant beneficial ownership stake in Matinas BioPharma Holdings, Inc., acquired through a private placement of convertible preferred stock and warrants, with plans to seek board representation.

Chaim Herzog and 111 Equity Group LLC have filed an amended Schedule 13D, revealing a 3.61% beneficial ownership in Matinas Biopharma Holdings, Inc. and indicating potential discussions regarding the company's strategy and governance.

Hezbay Holdings LLC has disclosed a beneficial ownership of 9.54% in Matinas BioPharma Holdings Inc. common stock as of July 13, 2026.

Highbridge Capital Management, LLC has reported a complete divestment of its beneficial ownership in Matinas BioPharma Holdings, Inc., reducing its stake to 0%.

David E. Lazar has disclosed a 9.81% beneficial ownership stake in Matinas BioPharma Holdings, Inc., holding 545,000 shares of common stock.

Highbridge Capital Management, LLC has reported an 8.4% beneficial ownership stake in Matinas BioPharma Holdings, Inc., primarily through warrants.